Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280046 | 0.82 | RAB9A (0.55) | LMNAALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL1107001 | 0.77 | LMNA (0.62) | LMNAFFAR2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1279996 | 0.77 | POLB (0.52) | LMNAALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL5838495 | 0.77 | CA1 (0.49) | LMNAALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL564354 | 0.76 | — | — | |
| SCHEMBL8752170 | 0.75 | ADRA1A (0.56) | LMNAFFAR2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL13525912 | 0.73 | L3MBTL1 (0.56) | LMNAFFAR2ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL20603903 | 0.72 | — | — | |
| SCHEMBL13694514 | 0.72 | MAPT (0.55) | FFAR2ALDH1A1HPGDHSD17B10RAB9A | |
| SCHEMBL11174268 | 0.72 | FFAR2 (0.57) | LMNAFFAR2ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575144-B2 | Beta-lactamase inhibitory compounds | SOUTHERN METHODIST UNIVERSITY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130079318-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | SOUTHERN METHODIST UNIVERSITY (US) | 2013-03-28 | — | — | US | disclosed |
| US-8299051-B2 | Beta-lactamase inhibitory compounds | SOUTHERN METHODIST UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20100009954-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | SOUTHERN METHODIST UNIVERSITY | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | LMNA 1490/4885FFAR2 4342/4885CSNK2A2 458/4885 |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | LMNA 1490/4885FFAR2 4342/4885CSNK2A2 458/4885 |
| US-20130079318-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | MGAM, GUSB, LCT | LMNA 1042/4885FFAR2 4753/4885CSNK2A2 3217/4885 |
| US-20100009954-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | MGAM, GUSB, LCT | LMNA 1042/4885FFAR2 4753/4885CSNK2A2 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.